LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antigen Profiling of Colorectal Cancer Uses Fluorescence Multiplexing

By LabMedica International staff writers
Posted on 06 Oct 2010
Print article
Surface antigen profiling of colorectal cancer (CRC) tissue has been achieved using antibody microarrays with fluorescence multiplexing.

The profiling method disaggregates CRC and normal intestinal mucosal tissues to produce suspensions of viable single cells, which are then captured on customized antibody microarrays recognizing 122 different surface antigens.

A study was carried out at the University of Sydney, (Sydney, NSW, Australia) to investigate the surface antigens of surgical samples from 40 CRC patients. Cell binding patterns are recorded by optical scanning of microarrays provide a surface profile of antigens on the cells. The DotScan Microarrays were custom-made at Medsaic Pty Ltd., (Eveleigh, NSW, Australia). Subpopulations of cells bound on the microarray were profiled by fluorescence multiplexing using monoclonal antibodies tagged with Quantum Dots or other fluorescent dyes.

Statistical analysis revealed significant differences between profiles for CRC samples and mucosal controls. Hierarchical clustering of CRC data identified several disease clusters that showed some correlation with clinicopathological stage as determined by conventional histopathological analysis. Fluorescence multiplexing using Phycoerythrin- or Alexa Fluor 647-conjugated antibodies was more effective than multiplexing with antibodies labeled with Quantum Dots. This relatively simple method yields a large amount of information for each patient sample and, with further application, should provide disease signatures, and enable the identification of patients with good or poor prognosis.

While the small size of CRC samples precluded separation of mixed CRC populations into subsets of interest prior to profiling, fluorescence multiplexing was used to profile T-cells (CD3+) and epithelial cell adhesion molecule (EpCAM)-expressing cells of epithelial origin in CRC and corresponding normal intestinal mucosa. The study was published in April 2010 issue of the Journal of Immunological Methods.

Related Links:
University of Sydney
Medsaic Pty Ltd.



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.